文献速递糖尿病

全自动胰岛素输送系统的安全性与可行性:FCL@Home多中心随机临床试验

Safety and Feasibility of a Fully Automated Insulin Delivery System: FCL@Home, a Multicenter Randomized Clinical Trial in Individuals With Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2026-01-01

本研究在1型糖尿病患者中评估了无需餐前大剂量 Announcement 的全自动胰岛素输送系统AIDANET在监督和家庭环境中的安全性与可行性。采用随机交叉设计,比较全闭环(FCL)与常规治疗(UC),主要终点为UC第二周与FCL家庭使用周的平均传感器葡萄糖(MSG)变化。结果显示FCL显著改善MSG(178 vs 164 mg/dL,P=0.0058),并改善范围内时间等指标,低血糖时间非劣效。

要点

  • FCL系统无需餐时大剂量,显著降低平均传感器葡萄糖(178→164 mg/dL)。
  • 范围内时间(70-180 mg/dL)和tight range时间显著改善,主要夜间获益。
  • 低血糖时间(<70和<54 mg/dL)非劣效于常规治疗。

核心结论

  • FCL治疗使用AIDANET系统可显著改善平均血糖控制,同时免除餐时大剂量需求,适用于广泛的T1D人群。

研究设计与样本

  • 多中心随机交叉研究,在美国三个中心入组成人(>25岁)、年轻成人(18-25岁)和青少年(14-18岁)T1D患者。
  • 共34名参与者完成研究(12成人、10年轻成人、12青少年),平均年龄25.4±12.6岁,62%女性,平均HbA1c 8.0±1.1%,94%在UC期间使用混合闭环。
  • 参与者先监督环境下使用FCL约5天,随后家庭使用约7天;主要终点为UC第二周与FCL家庭使用周的平均传感器葡萄糖(MSG)变化。

主要发现

  • MSG从178 mg/dL(UC)改善至164 mg/dL(FCL),P=0.0058。
  • 范围内时间(70-180 mg/dL)、tight range时间(70-140 mg/dL)及高于范围时间(>180和>250 mg/dL)均显著改善,主要发生在夜间。
  • 低于70和低于54 mg/dL的时间百分比在FCL与UC相比显著非劣效。

临床怎么用

  • 对于广泛T1D人群,FCL系统可在无需餐时大剂量情况下改善血糖控制,尤其夜间血糖。
  • 低血糖风险非劣效于常规治疗,支持FCL在家庭环境中的可行性。

局限性

  • 样本量较小(34人),研究周期较短(FCL家庭使用约7天)。
  • 未报告长期安全性或有效性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Automated insulin delivery (AID) requiring manual premeal boluses are the standard of care for people with type 1 diabetes (T1D). We evaluated the safety and feasibility of the Automated Insulin Delivery as an Adaptive NETwork (AIDANET) system used without meal announcements in both supervised and home settings across a diverse population of people with T1D. RESEARCH DESIGN AND METHODS: Adults (age >25 years), young adults (age 18-25 years), and adolescents (age 14-18 years) were enrolled at three sites in the U.S. to compare the AIDANET system used in fully closed-loop (FCL) with usual care (UC) in a randomized crossover study. Participants spent ∼5 days using FCL in a supervised environment followed by ∼7 days of use at home. The prespecified primary outcome was defined as the change in mean sensor glucose (MSG) between the 2nd week of UC and the week of the FCL at-home period. RESULTS: Overall, 34 participants (12 adults, 10 young adults, 12 adolescents; mean age 25.4 ± 12.6 years; 62% female; mean HbA1c 8.0 ± 1.1%; 94% hybrid closed loop users during UC) completed the study. MSG improved from 178 to 164 mg/dL (UC vs. FCL P = 0.0058). The percentages of time in range (70-180 mg/dL), time in tight range (70-140 mg/dL), and time above range (>180 mg/dL and >250 mg/dL) also significantly improved, primarily overnight. The percentage of time <70 and <54 mg/dL were significantly noninferior in FCL compared with UC. CONCLUSIONS: FCL therapy with the AIDANET system can significantly improve average glycemic control while removing the need for mealtime bolusing for a broad population of people with T1D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Moscoso-Vasquez M, Ekhlaspour L, Brown SA, et al. Safety and Feasibility of a Fully Automated Insulin Delivery System: FCL@Home, a Multicenter Randomized Clinical Trial in Individuals With Type 1 Diabetes. Diabetes Care. 2026. PMID: 41401082. doi:10.2337/dc25-1526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。